Navigation Links
Bayer HealthCare Pharmaceuticals Supports New Jersey Governor's School in the Sciences at Drew University
Date:7/22/2010

WAYNE, N.J., July 22 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals is pleased to announce it will support the New Jersey Governor's School in the Sciences (NJGSS) at Drew University this summer.  This is the second year in a row that Bayer HealthCare Pharmaceuticals has sponsored the program, which is the longest running of the active Governor's schools.  

(Photo: http://photos.prnewswire.com/prnh/20100722/NY39266 )

(Photo: http://www.newscom.com/cgi-bin/prnh/20100722/NY39266 )

The NJGSS offers courses in neuroscience, cell biology, physics, mathematics, anthropology and chemistry. Eighty-five of the state's top math and science students representing 18 of New Jersey's 21 counties will participate in the three week program, which runs from July 11-31.  

"We challenge these outstanding high school juniors with an academic program that they usually would not experience until well into their college careers," said Dr. David Miyamoto, director of the NJGSS at Drew University.  "Students work together in teams on highly experiential research projects that lead to the writing of scientific-style papers and oral presentations of the work at a scientific-style conference."  

"As a company dedicated to science, we recognize the importance of unique programs like the NJGSS," said Sandra J. Oliver, vice president, public policy and government affairs at Bayer.  Located in Wayne, the company's aim is to develop and manufacture products that will improve human health by diagnosing, preventing and treating diseases.

Additionally, Making Science Make Sense® (MSMS) is Bayer's company-wide initiative that advances science literacy through hands-on, inquiry-based science education, employee volunteerism and a public education campaign. Currently, 12 Bayer sites around the country operate local MSMS programs, which together represent a national volunteer corps of more than 1,000 employees.

"Bayer HealthCare's generous support of the New Jersey Governor's School in the Sciences will continue to expose high school students throughout the state to opportunities and future careers in the sciences," said Governor Chris Christie.  "I want to thank Bayer for its contribution to this worthwhile program.  It is the support of local companies like Bayer that is invaluable in helping promote scientific learning, problem solving skills and leadership training to students throughout the Garden State."

About Drew University -- Founded in 1867, Drew is a selective, independent, coeducational university with a total enrollment of more than 2,700 students in its College of Liberal Arts, Caspersen School of Graduate Studies and Theological School.  Widely recognized for academic excellence and its tight-knit, diverse community, Drew is routinely listed among the nation's top colleges by The Princeton Review.  Having won Rhodes, Fulbright, Truman, Goldwater, Marshall and National Science Foundation scholarships, Drew students are among the best in the nation.  The university is one of three in New Jersey with a chapter of Phi Beta Kappa, the nation's most prestigious academic honor society.

About Bayer HealthCare Pharmaceuticals Inc. -- Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a division of Bayer AG. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Women's Healthcare, Diagnostic Imaging, Specialized Therapeutics, Hematology/Cardiology and Oncology. The company's aim is to discover and manufacture products that will improve human health worldwide by diagnosing, preventing and treating diseases.


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... FRISCO, Texas , Oct. 11, 2017 /PRNewswire/ ... healthcare services, has amplified its effort during National ... patients about hereditary cancer risks. ... Journal of Clinical Oncology calculated that more than ... to have inherited mutations in BRCA1 or BRCA2 and ...
(Date:10/10/2017)... Oct. 10, 2017   West Pharmaceutical Services, Inc. ... for injectable drug administration, today shared the results of ... for improving the intradermal administration of polio vaccines. The ... Summit in May 2017 by Dr. Ondrej Mach ... World Health Organization (WHO), and recently published in the ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ... today the introduction of an innovative new design of the shoulder pad. The ... get maximum comfort while controlling your pain while using cold therapy. By utilizing ice ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
(Date:10/12/2017)... ... 12, 2017 , ... Health Literacy Innovations (HLI), creator of ... and the Cancer Patient Education Network (CPEN), an independent professional organization that shares ... strategic alliance. , As CPEN’s strategic partner, HLI will help support CPEN ...
Breaking Medicine News(10 mins):